Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label multicenter study of sunitinib malate capsules in advanced or metastatic NSCLC with uncommon non-resistance EGFR mutations
CTR20210196Phase 2Active
- Sponsor
- Suzhong Pharmaceutical Group
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Suzhong Pharmaceutical Group. Started Dec 2021; status: active.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210196.